Facile construction of gefitinib‐loaded zeolitic imidazolate framework nanocomposites for the treatment of different lung cancer cells
Kalaivani Aiyasamy,
Malathi Ramasamy,
Abdurahman Hajinur Hirad
et al.
Abstract:Gefitinib (GET) is a revolutionary targeted treatment inhibiting the epidermal growth factor receptor's tyrosine kinase action by competitively inhibiting the ATP binding site. In preclinical trials, several lung cancer cell lines and xenografts have demonstrated potential activity with GET. Response rates neared 25% in preclinical trials for non‐small cell lung cancer. Here, we describe the one‐pot synthesis of GET@ZIF‐8 nanocomposites (NCs) in pure water, encapsulating zeolitic imidazolate framework 8 (ZIF‐8… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.